Summary
Global Markets Direct’s, ‘Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Otsuka Holdings Co., Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd.
- The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Otsuka Holdings Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Otsuka Holdings Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Otsuka Holdings Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Otsuka Holdings Co., Ltd. Snapshot 7
Otsuka Holdings Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Otsuka Holdings Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Otsuka Holdings Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Otsuka Holdings Co., Ltd. - Drug Profiles 22
(carteolol hydrochloride + latanoprost) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(tipiracil hydrochloride + trifluridine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levetiracetam 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ponatinib hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tolvaptan 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
(aripiprazole + sertraline) 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(gimeracil + oteracil + tegafur) 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
aripiprazole ER 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AVP-786 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
brexpiprazole 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
delamanid 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
nabiximols 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rebamipide 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(dextromethorphan + quinidine sulfate) 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OCV-501 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OPA-15406 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OPS-2071 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
probucol 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tetomilast 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
OPA-6566 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
OPB-111001 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LPC-01 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LUAF-20513 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
OCVC-02 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OPB-111077 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPC-108459 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
OPC-39436 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
OPC-64005 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OPC-28326 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Otsuka Holdings Co., Ltd. - Pipeline Analysis 71
Otsuka Holdings Co., Ltd. - Pipeline Products by Target 71
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 73
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 74
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 75
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 77
Otsuka Holdings Co., Ltd. - Dormant Projects 113
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 114
Discontinued Pipeline Product Profiles 114
(gimeracil + oteracil + tegafur) 114
(tipiracil hydrochloride + trifluridine) 114
AVP-13358 114
AZD-2479 115
brexpiprazole 115
dasatinib 115
OCV-101 115
OPB-31121 115
OPB-51602 115
rebamipide 115
Otsuka Holdings Co., Ltd. - Company Statement 117
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 118
Head Office 118
Other Locations & Subsidiaries 118
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 121
Disclaimer 122
List of Tables
Otsuka Holdings Co., Ltd., Key Information 7
Otsuka Holdings Co., Ltd., Key Facts 7
Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2016 9
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016 12
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016 13
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 14
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016 15
Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 16
Otsuka Holdings Co., Ltd. - Pre-Registration, 2016 17
Otsuka Holdings Co., Ltd. - Phase III, 2016 18
Otsuka Holdings Co., Ltd. - Phase II, 2016 19
Otsuka Holdings Co., Ltd. - Phase I, 2016 20
Otsuka Holdings Co., Ltd. - Preclinical, 2016 21
Otsuka Holdings Co., Ltd. - Pipeline by Target, 2016 71
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016 73
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016 74
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 75
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2016 77
Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2016 113
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2016 114
Otsuka Holdings Co., Ltd., Other Locations 118
Otsuka Holdings Co., Ltd., Subsidiaries 118
List of Figures
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Indication, 2016 9
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016 12
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016 13
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 14
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016 15
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Target, 2016 71
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016 73
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016 74
Otsuka Holdings Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 75
